Hi Curro, I am on a Lu177 trial at Peter Mac in Melbourne.The principle aim of this study is to test the safety and effectiveness of prostate specific membrane antigen(PSMA)labeled with the radioneculide Lutetium177 (LU177) in men with metastatic prostate cancer refractory to hormonal therapy and chemotherapy. The trial limit is 30. Regrettably but I don't know how many have been recruited thus far. I have had 3 infusions to date with one more to come. The team members conducting this trial